Newsroom | 87696 results

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer’s disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer’s disease, for patients being evaluated for cognitive complaints through a simpl...

DUBLIN--(BUSINESS WIRE)--The "Bispecific Antibodies Market Industry Trends and Global Forecasts to 2035: By Therapeutic Area, Mechanism of Action, Target Antigen, Antibody Format, Key Geographical Regions and Key Players" report has been added to ResearchAndMarkets.com's offering. The global bispecific antibodies market is estimated to grow from USD 5.6 billion in 2025, to USD 16.8 billion by 2035, at a CAGR of 9.5% during the forecast period, to 2035. The discovery of the therapeutic potential...

DUBLIN--(BUSINESS WIRE)--The "Chondrosarcoma Market - A Global and Regional Analysis: Focus on Type, Treatment Type, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. Chondrosarcoma is a rare malignant tumor of cartilage-forming tissue, most commonly affecting bones such as the pelvis, femur, and humerus. Subtypes include conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma. Advancements in radiographic imaging, next...

DALLAS--(BUSINESS WIRE)--AIS Healthcare has been awarded a group purchasing agreement for 503A intrathecal compounded medications with Premier, Inc., effective July 1, 2025. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for sterile, patient-specific intrathecal pain pump medications. In addition, to assist with compliance policies, this agreement with Premier will provide member hospitals with site audit e...

NEW YORK--(BUSINESS WIRE)--BlinkRx, the nation's leading prescription lifecycle management platform, today announced the launch of Operation Access Now, a rapid deployment initiative that enables pharmaceutical manufacturers to build and launch direct-to-patient (DTP) and direct‑to‑business (DTB) channels that expand medication access and deliver pricing transparency in as little as 21 days. This program comes at a moment of growing urgency across the life sciences industry. As traditional acce...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leader in AI-powered solutions for drug discovery and development, has been honored with the “AI-based Drug Discovery Solution of the Year” award in the 8th annual AI Breakthrough Awards program. AI Breakthrough is a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market. BostonGene’s breakthrough AI platform is transforming oncology research and drug d...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab and lenalidomide (R2) versus R2 alone for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study met its dual primary endpoints of overall response rate (ORR, p-value < 0.0001) and progression-free survival (PFS, HR 0.21, p-valu...

ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of TolaSure™, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex (EB Simplex). EB Simplex is a rare, inherited skin disorder that causes painful blistering...

TORONTO--(BUSINESS WIRE)--ProteinQure, a leader in computational protein drug discovery, today announced it has received regulatory clearance from both the U.S. Food and Drug Administration (FDA) and Health Canada to initiate a Phase I clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of its lead candidate, PQ203. The FDA has also granted PQ203 Fast Track designation for patients with triple negative breast cancer, recognizing the therapy’s potent...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ThinkBio.Ai® and UST Partner to Strengthen AI Enablement Capabilities for Biopharma and Healthcare Organizations....